Sophie Cohen1, Jacqueline A Ter Stege2, Gert J Geurtsen3, Henriette J Scherpbier1, Taco W Kuijpers1, Peter Reiss4, Ben Schmand5, Dasja Pajkrt1. 1. Department of Pediatric Hematology, Immunology, and Infectious Diseases. 2. Department of Pediatric Hematology, Immunology, and Infectious Diseases Psychosocial Department, Emma Children's Hospital, Academic Medical Center, University of Amsterdam. 3. Department of Neurology, Academic Medical Center Amsterdam. 4. Department of Global Health, Academic Medical Center, University of Amsterdam, and Amsterdam Institute of Global Health and Development HIV Monitoring Foundation Department of Internal Medicine, Division of Infectious Diseases, Center for Infection and Immunity Amsterdam, Academic Medical Center. 5. Department of Neurology, Academic Medical Center Amsterdam Department of Psychology, University of Amsterdam, The Netherlands.
Abstract
BACKGROUND: Despite the declining incidence of severe neurological complications such as HIV encephalopathy, human immunodeficiency virus (HIV) infection in children is still associated with a range of cognitive problems. Although most HIV-infected children in industrialized countries are immigrants with a relatively low socioeconomic status (SES), cognitive studies comparing HIV-infected children to SES-matched controls are lacking. METHODS: This cross-sectional study included perinatally HIV-infected children and controls matched for age, sex, ethnicity, and SES, who completed a neuropsychological assessment evaluating intelligence, information processing speed, attention, memory, executive function, and visual-motor function. Multivariate normative comparison was used to assess the prevalence of cognitive impairment in the HIV-infected group. Multivariable regression analyses were performed to identify HIV- and combination antiretroviral therapy-related factors associated with cognitive performance. RESULTS: In total, 35 perinatally HIV-infected children (median age, 13.8 years; median CD4 count, 770 × 10(6) cells/L; 83% with undetectable HIV RNA) and 37 healthy children (median age, 12.1 years) were included. HIV-infected children scored lower than the healthy controls on all cognitive domains (eg, intelligence quotient [IQ], 76 [standard deviation {SD}, 15.7] vs 87.5 [SD, 13.6] for HIV-infected vs healthy children; P = .002). Cognitive impairment was found in 6 HIV-infected children (17%). The Centers for Disease Control and Prevention (CDC) clinical category at HIV diagnosis was inversely associated with verbal IQ (CDC clinical category C: coefficient -22.98; P = .010). CONCLUSIONS: Our results show that cognitive performance of HIV-infected children is poor compared with that of SES-matched healthy controls. Gaining insight into these cognitive deficits is essential, as subtle impairments may progress to more pronounced complications that will influence future intellectual performance, job opportunities, and community participation of HIV-infected children.
BACKGROUND: Despite the declining incidence of severe neurological complications such as HIV encephalopathy, human immunodeficiency virus (HIV) infection in children is still associated with a range of cognitive problems. Although most HIV-infectedchildren in industrialized countries are immigrants with a relatively low socioeconomic status (SES), cognitive studies comparing HIV-infectedchildren to SES-matched controls are lacking. METHODS: This cross-sectional study included perinatally HIV-infectedchildren and controls matched for age, sex, ethnicity, and SES, who completed a neuropsychological assessment evaluating intelligence, information processing speed, attention, memory, executive function, and visual-motor function. Multivariate normative comparison was used to assess the prevalence of cognitive impairment in the HIV-infected group. Multivariable regression analyses were performed to identify HIV- and combination antiretroviral therapy-related factors associated with cognitive performance. RESULTS: In total, 35 perinatally HIV-infectedchildren (median age, 13.8 years; median CD4 count, 770 × 10(6) cells/L; 83% with undetectable HIV RNA) and 37 healthy children (median age, 12.1 years) were included. HIV-infectedchildren scored lower than the healthy controls on all cognitive domains (eg, intelligence quotient [IQ], 76 [standard deviation {SD}, 15.7] vs 87.5 [SD, 13.6] for HIV-infected vs healthy children; P = .002). Cognitive impairment was found in 6 HIV-infectedchildren (17%). The Centers for Disease Control and Prevention (CDC) clinical category at HIV diagnosis was inversely associated with verbal IQ (CDC clinical category C: coefficient -22.98; P = .010). CONCLUSIONS: Our results show that cognitive performance of HIV-infectedchildren is poor compared with that of SES-matched healthy controls. Gaining insight into these cognitive deficits is essential, as subtle impairments may progress to more pronounced complications that will influence future intellectual performance, job opportunities, and community participation of HIV-infectedchildren.
Authors: C Paula Lewis-de Los Angeles; Paige L Williams; Yanling Huo; Shirlene D Wang; Kristina A Uban; Megan M Herting; Kathleen Malee; Ram Yogev; John G Csernansky; Sharon Nichols; Russell B Van Dyke; Elizabeth R Sowell; Lei Wang Journal: Brain Behav Immun Date: 2017-01-10 Impact factor: 7.217
Authors: Reuben N Robbins; R Zimmerman; R Korich; J Raymond; C Dolezal; C J Choi; C S Leu; N Nguyen; K Malee; A Wiznia; E J Abrams; C A Mellins Journal: AIDS Care Date: 2019-06-07
Authors: Heather Carryl; Melanie Swang; Jerome Lawrence; Kimberly Curtis; Herman Kamboj; Koen K A Van Rompay; Kristina De Paris; Mark W Burke Journal: ACS Chem Neurosci Date: 2015-06-19 Impact factor: 4.418
Authors: Katrina D Hermetet-Lindsay; Katharine F Correia; Paige L Williams; Renee Smith; Kathleen M Malee; Claude A Mellins; Richard M Rutstein Journal: AIDS Behav Date: 2017-09
Authors: Manoj K Sarma; Margaret A Keller; Paul M Macey; David E Michalik; Judy Hayes; Karin Nielsen-Saines; Jaime Deville; Joseph A Church; Irwin Walot; M Albert Thomas Journal: J Neurovirol Date: 2019-01-04 Impact factor: 2.643
Authors: Nicole Phillips; Taryn Amos; Caroline Kuo; Jacqueline Hoare; Jonathan Ipser; Kevin G F Thomas; Dan J Stein Journal: Pediatrics Date: 2016-10-11 Impact factor: 7.124
Authors: Alexandra Buda; Owen Dean; Heather R Adams; Sylvia Mwanza-Kabaghe; Michael J Potchen; Esau G Mbewe; Pelekelo P Kabundula; Sarah Mohajeri Moghaddam; Milimo Mweemba; Beauty Matoka; Manoj M Mathews; Gretchen L Birbeck; David R Bearden Journal: Pediatr Neurol Date: 2019-08-06 Impact factor: 3.372